Search Results

There are 4411 results for: content related to: Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users

  1. You have free access to this content
    An evaluation of gene–gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol

    Journal of Thrombosis and Haemostasis

    Volume 10, Issue 5, May 2012, Pages: 767–772, R. M. F. VAN SCHIE, A. M. V. BABAJEFF, T. SCHALEKAMP, J. A. M. WESSELS, S. LE CESSIE, A. de BOER, F. J. M. VAN DER MEER, E. VAN MEEGEN, T. I. VERHOEF, F. R. ROSENDAAL, A. H. MAITLAND-VAN DER ZEE and FOR THE EU-PACT STUDY GROUP

    Version of Record online : 2 MAY 2012, DOI: 10.1111/j.1538-7836.2012.04694.x

  2. You have free access to this content
    Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon

    British Journal of Clinical Pharmacology

    Volume 77, Issue 4, April 2014, Pages: 626–641, Talitha I. Verhoef, William K. Redekop, Ann K. Daly, Rianne M. F. van Schie, Anthonius de Boer and Anke-Hilse Maitland-van der Zee

    Version of Record online : 20 MAR 2014, DOI: 10.1111/bcp.12220

  3. The enantiomers of phenprocoumon: Pharmacodynamic and pharmacokinetic studies

    Clinical Pharmacology & Therapeutics

    Volume 20, Issue 3, September 1976, Pages: 342–349, Eberhard Jahnchen, Thomas Meinertz, Hans-Joachim Gilfrich, Ulrich Groth and Albrecht Martini

    Version of Record online : 4 JAN 2016, DOI: 10.1002/cpt1976203342

  4. VKORC1 and CYP2C9 Genotypes and Phenprocoumon Anticoagulation Status: Interaction Between both Genotypes Affects Dose Requirement

    Clinical Pharmacology & Therapeutics

    Volume 81, Issue 2, February 2007, Pages: 185–193, T Schalekamp, B P Brassé, J F M Roijers, E van Meegen, F J M van der Meer, E M van Wijk, A C G Egberts and A de Boer

    Version of Record online : 27 DEC 2006, DOI: 10.1038/sj.clpt.6100036

  5. You have free access to this content
    A New Algorithm for Weekly Phenprocoumon Dose Variation in a Southern Brazilian Population: Role for CYP2C9, CYP3A4/5 and VKORC1 Genes Polymorphisms

    Basic & Clinical Pharmacology & Toxicology

    Volume 114, Issue 4, April 2014, Pages: 323–329, Mariana R. Botton, Patrícia P. Viola, Eliane Bandinelli, Tiago L. L. Leiria, Luis E. P. Rohde and Mara H. Hutz

    Version of Record online : 7 DEC 2013, DOI: 10.1111/bcpt.12172

  6. Fluorescent investigations of binding of phenprocoumon to α1-acid glycoprotein

    Journal of Pharmaceutical Sciences

    Volume 76, Issue 8, August 1987, Pages: 646–649, M. Otagiri, T. Maruyama, T. Imai and Y. Imamura

    Version of Record online : 16 SEP 2006, DOI: 10.1002/jps.2600760812

  7. The effect of sulfinpyrazone on the disposition of pseudoracemic phenprocoumon in humans

    Clinical Pharmacology & Therapeutics

    Volume 42, Issue 3, September 1987, Pages: 312–319, Larry D Heimark, Stephen Toon, Milo Gibaldi, William F Trager, Robert A O'Reilly and Darklis A Goulart

    Version of Record online : 21 SEP 1987, DOI: 10.1038/clpt.1987.154

  8. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status

    Clinical Pharmacology & Therapeutics

    Volume 76, Issue 5, November 2004, Pages: 409–417, Tom Schalekamp, Mirjam Oosterhof, Erik van Meegen, Felix J. M. van Der Meer, Jean Conemans, Mirjam Hermans, Irma Meijerman and Anthonius de Boer

    Version of Record online : 14 NOV 2004, DOI: 10.1016/j.clpt.2004.08.006

  9. Does additional confounder information alter the estimated risk of bleeding associated with phenprocoumon use—results of a two-phase study

    Pharmacoepidemiology and Drug Safety

    Volume 21, Issue 5, May 2012, Pages: 535–545, Sigrid Behr, Walter Schill and Iris Pigeot

    Version of Record online : 2 FEB 2012, DOI: 10.1002/pds.3193

  10. You have free access to this content
    Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment

    Journal of Thrombosis and Haemostasis

    Volume 9, Issue 1, January 2011, Pages: 109–118, M. WATZKA, C. GEISEN, C. G. BEVANS, K. SITTINGER, G. SPOHN, S. ROST, E. SEIFRIED, C. R. MÜLLER and J. OLDENBURG

    Version of Record online : 7 JAN 2011, DOI: 10.1111/j.1538-7836.2010.04095.x

  11. You have free access to this content
    Metformin use decreases the anticoagulant effect of phenprocoumon

    Journal of Thrombosis and Haemostasis

    Volume 12, Issue 6, June 2014, Pages: 887–890, J. C. F. Wijnen, I. R. van de Riet, W. M. Lijfering and F. J. M. van der Meer

    Version of Record online : 10 JUN 2014, DOI: 10.1111/jth.12578

  12. Mass spectral analysis of phenprocoumon and O-alkyl phenprocoumons

    Biomedical & Environmental Mass Spectrometry

    Volume 18, Issue 4, April 1989, Pages: 224–232, J. X. de Vries and D. Krauss

    Version of Record online : 13 APR 2005, DOI: 10.1002/bms.1200180404

  13. Influence of Fatty Acids on the Binding of Warfarin and Phenprocoumon to Human Serum Albumin with Relation to Anticoagulant Therapy

    Journal of Pharmacy and Pharmacology

    Volume 48, Issue 8, August 1996, Pages: 870–875, Henrik Vorum and Bent Honoré

    Version of Record online : 12 APR 2011, DOI: 10.1111/j.2042-7158.1996.tb03990.x

  14. You have free access to this content
    Stereoselective drug distribution and anticoagulant potency of the enantiomers of phenprocoumon in rats

    Journal of Pharmacy and Pharmacology

    Volume 29, Issue 1, September 1977, Pages: 266–271, W. SCHMIDT and E. JÄHNCHEN

    Version of Record online : 12 APR 2011, DOI: 10.1111/j.2042-7158.1977.tb11309.x

  15. You have free access to this content
    The effect of omeprazole and esomeprazole on the maintenance dose of phenprocoumon

    British Journal of Clinical Pharmacology

    Volume 74, Issue 6, December 2012, Pages: 1068–1069, Talitha I. Verhoef, Miranda J. L. Zuurhout, Rianne M. F. van Schie, William K. Redekop, Felix J. M. van der Meer, Saskia le Cessie, Tom Schalekamp, Anthonius de Boer and Anke Hilse Maitland-van der Zee

    Version of Record online : 13 NOV 2012, DOI: 10.1111/j.1365-2125.2012.04295.x

  16. Age-dependent differences in the effect of phenprocoumon on the vitamin K1-epoxide cycle in rats

    Journal of Pharmacy and Pharmacology

    Volume 32, Issue 1, September 1980, Pages: 828–832, DIETMAR TRENK, DIETER BEERMANN, FRANZ OESCH and EBERHARD JÄHNCHEN

    Version of Record online : 12 APR 2011, DOI: 10.1111/j.2042-7158.1980.tb13085.x

  17. GLC determination of plasma concentrations of phenprocoumon

    Journal of Pharmaceutical Sciences

    Volume 65, Issue 3, March 1976, Pages: 387–391, K. K. Midha, J. W. Hubbard, J. K. Cooper and I. J. McGilveray

    Version of Record online : 18 SEP 2006, DOI: 10.1002/jps.2600650318

  18. You have free access to this content
    Pharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol.

    British Journal of Clinical Pharmacology

    Volume 17, Issue S1, February 1984, Pages: 97S–102S, H Spahn, W Kirch, E Mutschler, EE Ohnhaus, NR Kitteringham, HJ Logering and D Paar

    Version of Record online : 26 JUL 2012, DOI: 10.1111/j.1365-2125.1984.tb02439.x

  19. You have free access to this content
    Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon

    British Journal of Haematology

    Volume 117, Issue 4, June-II 2002, Pages: 940–946, Alain P. A. Gadisseur, Felix J. M. Van Der Meer, Henk J. Adriaansen, Stephan D. Fihn and Frits R. Rosendaal

    Version of Record online : 10 JUN 2002, DOI: 10.1046/j.1365-2141.2002.03493.x

  20. Metabolic fate of phenprocoumon in humans

    Journal of Pharmaceutical Sciences

    Volume 74, Issue 10, October 1985, Pages: 1037–1040, Stephen Toon, Larry D. Heimark, William F. Trager and Robert A. O'Reilly

    Version of Record online : 17 SEP 2006, DOI: 10.1002/jps.2600741003